PROTAC MLKL Degrader-2
PROTAC MLKL Degrader-2 is an orally active and highly selective mixed lineage kinase domain-like pseudokinase (MLKL) PROTAC degrader with a DC50 of 0.012 μM. PROTAC MLKL Degrader-2 recruits the CRBN E3 ubiquitin ligase to form a ternary complex, leading to ubiquitination of MLKL and its degradation via a proteasome-dependent pathway. PROTAC MLKL Degrader-2 inhibits necroptosis, reduces ROS production, restores mitochondrial function, and ameliorates lysosomal dysfunction induced by necroptotic stimuli. PROTAC MLKL Degrader-2 degrades MLKL in xenograft mouse models. PROTAC MLKL Degrader-2 can be used in cancer-related research.
(Pink: Mixed Lineage Kinase ligand (HY-169073); Blue: Cereblon ligand (HY-14658); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3103327-20-1
- Formula: C36H35N9O9S
- Molecular Weight:769.78
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
IC50 & Target
MLKL[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HT-29 | EC50 |
0.017 μM
Compound: MP-11
|
Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 24 hrs by CCK8 assay
Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 24 hrs by CCK8 assay
|
[PMID: 39180479] |
| HT-29 | EC50 |
0.019 μM
Compound: MP-11
|
Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 4 hrs followed by fresh medium replacement without compound by CCK8 assay
Anti-necroptotic activity against TSZ-treated human HT-29 cells assessed as cell survival incubated for 4 hrs followed by fresh medium replacement without compound by CCK8 assay
|
[PMID: 39180479] |
| HT-29 | IC50 |
>40 μM
Compound: MP-11
|
Cytotoxicity against human HT-29 cells
Cytotoxicity against human HT-29 cells
|
[PMID: 39180479] |
In Vitro
PROTAC MLKL Degrader-2 (MP-11) covalently binds to the Cys86 residue of recombinant human MLKL protein via loss of its methanesulfonyl group, and exhibits extremely high whole-proteome selectivity for MLKL in HT-29 cells[1].
PROTAC MLKL Degrader-2 (24 h) degrades MLKL in HT-29 cells, with a DC50 of 0.012 μM and a maximum degradation rate of 95.06%[1].
PROTAC MLKL Degrader-2 (0.01-10 μM; 24 h) potently and selectively protects human HT-29 and U937 cells from necroptosis (EC50 = 0.017 μM in HT-29 cells), but has no effect on mouse cells or apoptosis[1].
PROTAC MLKL Degrader-2 (10-300 nM) reduces the proportion of PI-positive necrotic HT-29 cells in a dose-dependent manner[1].
PROTAC MLKL Degrader-2 (10-300 nM; 0-12 h) efficiently degrades MLKL in HT-29 cells in a dose- and time-dependent manner in vitro, with rapid degradation activity and no effect on the upstream RIPK1 signaling pathway[1].
PROTAC MLKL Degrader-2 acts as a covalent MLKL degrader in HT-29 cells, retains activity after washout, and inhibits MLKL expression and trimerization for an extended period[1].
PROTAC MLKL Degrader-2 (1 μM; 6 h) inhibits the expression of pMLKL and prevents lysosomal membrane permeabilization in HT-29 cells treated with TSZ[1].
PROTAC MLKL Degrader-2 dose-dependently reduces ROS production and restores mitochondrial function in TSZ-treated HT-29 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human HT-29 colon adenocarcinoma cells, human U937 histiocytic lymphoma cells, mouse J774A.1 macrophage cells, mouse L929 fibroblast cells
-
Concentration:0.01, 0.03, 0.1, 0.3, 1, 3, 10 μM
-
Incubation Time:24 h
-
Result:Protected HT-29 and U937 human cells from TSZ-induced necroptosis in a dose-dependent manner, with an EC50 of 0.017 μM in HT-29 cells.
Showed no protective effect on mouse J774A.1 and L929 cells.
Showed no dose-dependent protective effect against TS-induced apoptosis in HT-29 cells.
-
Cell Line:HT-29 cells
-
Concentration:30 nM
-
Incubation Time:0, 1, 2, 4, 8, 12 h
-
Result:Caused dose-dependent degradation of MLKL in TSZ-treated HT-29 cells, with 30 nM MP-11 almost eliminating MLKL expression, without altering RIPK1 or pRIPK1 levels.
Under necroptotic conditions, MLKL showed marked degradation 2 h after MP-11 treatment, reaching ~95% degradation by 12 h.
Under normal conditions, MLKL was degraded within 2 h of MP-11 treatment, reaching ~90% degradation by 12 h.
-
Cell Line:HT-29 cells
-
Concentration:1 μM
-
Incubation Time:6 h
-
Result:Markedly decreased pMLKL expression and restored normal LAMP2 localization, indicating preserved lysosomal function.
Parmacokinetics
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 4 weeks old, specified pathogen-free grade)[1]
-
Dosage:40 mg/kg (i.v.)
40 mg/kg (p.o.) -
Administration:i.v.; single dose
p.o.; single dose -
Result:Caused an ~90% MLKL degradation rate in xenograft tumors.
Caused an ~72% MLKL degradation rate in xenograft tumors.
Reached tumor tissue concentrations of 224.2 ng/g at 1 hour post-administration and 176.18 ng/g at 24 hours post-administration via intravenous route.
Reached tumor tissue concentrations of 80.22 ng/g at 1 hour post-administration and 74.18 ng/g at 24 hours post-administration via oral route.
Showed no obvious side effects or major organ damage via either administration route.
Caused only a minor, transient body weight decrease in the initial 2 days via intravenous route.
Chemical Information
-
CAS No. 3103327-20-1
-
Molecular Weight 769.78
-
Formula C36H35N9O9S
-
SMILES
O=C(NC1=CC=CC(C#CCN(C(N(C2=O)C)=O)C3=C2N(C(S(C)(=O)=O)=N3)C)=C1)CN4CCN(C5=CC6=C(C=C5)C(N(C6=O)C7CCC(NC7=O)=O)=O)CC4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Splenic/Portal-Vein Liver Metastasis Xenograft
Splenic and portal-vein liver metastasis xenograft models deliver tumor cells into the portal circulation so that cells reach the liver first and form hepatic metastatic lesions; splenic injection uses the spleen as an access route to the portal system, while direct portal-vein injection introduces cells into the portal vein without requiring splenectomy. The assay detects liver colonization, intrahepatic tumor growth, tumor distribution, treatment response, survival, and liver-metastasis microenvironment changes; readouts include bioluminescence or fluorescence imaging, gross liver nodule counts, liver weight or tumor burden, histology, and survival.
-
Lysosome and acidic-vesicle live-cell staining
Lysosome and acidic-vesicle live-cell staining detects acidic intracellular compartments by using membrane-permeant acidotropic probes that accumulate in low-pH vesicles, including lysosomes, late endosomes, autolysosomes, and acidic phagosomes. LysoTracker staining is commonly used as an intensity-based readout of acidic lysosomal compartment abundance or enlargement, while acridine orange produces green fluorescence in less concentrated compartments and red fluorescence after concentration-dependent accumulation in acidic vesicular organelles. Loss or reduction of acridine-orange red signal can be used as a readout of lysosomal membrane permeabilization or reduced acidic-vesicle integrity. This protocol is designed for live cultured cells and can be adapted for fluorescence microscopy, high-content imaging, plate-reader readout, or flow cytometry when the selected literature supports the readout. Because these dyes report acidotropic accumulation rather than lysosome identity alone,
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Intraperitoneal/Peritoneal Dissemination Xenograft
Intraperitoneal (IP) or peritoneal dissemination xenograft models are based on the introduction of human cancer cells into the peritoneal cavity of immunodeficient mice, where they attach to peritoneal surfaces, form multicellular aggregates or spheroids, and progressively generate disseminated tumor nodules that mimic advanced peritoneal metastatic disease. These models are widely used to study ovarian cancer progression, tumor-microenvironment interactions, and intraperitoneal therapeutic responses, often incorporating bioluminescence or fluorescence imaging to longitudinally monitor tumor burden in vivo. The biological principle relies on the capacity of tumor cells such as SKOV3 or related ovarian carcinoma lines to survive in suspension, aggregate within ascites-like fluid, adhere to mesothelial surfaces, and invade peritoneal organs, thereby recapitulating human peritoneal carcinomatosis patterns observed in advanced disease.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PROTAC MLKL Degrader-2
- 3103327-20-1
- PROTAC MLKL Degrader2
- PROTAC MLKL Degrader 2
- PROTACs
- Mixed Lineage Kinase
- Reactive Oxygen Species (ROS)
- Necroptosis
- mixed lineage kinase domain-like pseudokinase
- reactive oxygen species
- necroptosis
- HT-29 cells
- U937 cells
- mitochondrial function
- MLKL
- apoptosis
- CRBN E3 ubiquitin ligase
- lysosomal dysfunction
- Inhibitor
- inhibitor
- inhibit